Profit

Buy Jubilant Life Sciences for Target of Rs 496: Daljeet Kohli

PUBLISHED ON: March 8, 2016 | Duration: 14 min, 58 sec

  
loading..
Daljeet Kohli, head of research at IndiaNivesh Securities, says Jubilant Life Sciences' pharma business has started to perform and its margins are expected to return to a trajectory of 20-25 per cent in the coming quarters.
ALSO WATCH
Sensex Gains Over 150 Points, Nifty Inches Towards 10,650

................................ Advertisement ................................

................................ Advertisement ................................